These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8868205)

  • 1. Hostility in heroin abusers subtypes: fluoxetine and naltrexone treatment.
    Gerra G; Fertonani G; Zaimovic A; Rota-Graziosi I; Avanzini P; Caccavari R; Delsignore R; Lucchini A
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Dec; 19(8):1225-37. PubMed ID: 8868205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggressive responding in abstinent heroin addicts: neuroendocrine and personality correlates.
    Gerra G; Zaimovic A; Moi G; Bussandri M; Bubici C; Mossini M; Raggi MA; Brambilla F
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):129-39. PubMed ID: 14687867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia.
    Krupitsky EM; Zvartau EE; Masalov DV; Tsoy MV; Burakov AM; Egorova VY; Didenko TY; Romanova TN; Ivanova EB; Bespalov AY; Verbitskaya EV; Neznanov NG; Grinenko AY; O'Brien CP; Woody GE
    J Subst Abuse Treat; 2006 Dec; 31(4):319-28. PubMed ID: 17084785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone and buprenorphine combination in the treatment of opioid dependence.
    Gerra G; Fantoma A; Zaimovic A
    J Psychopharmacol; 2006 Nov; 20(6):806-14. PubMed ID: 16401652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Naltrexone and fluoxetine for maintenance of remission in patients with heroin addiction: a double-blind randomized placebo-controlled trial].
    Krupitskiĭ EM; Zvartau EE; Tsoĭ-Podosenin MV; Masalov DV; Burakov AM; Egorova VIu; Didenko TIu; Romanova TN; Ivanova EB; Bespalov AIu; Verbitskaia EV; Neznanov NG; Grineneko AIa; O'Brien C; Woody D
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(5 Pt 2):44-54. PubMed ID: 21322147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggressive responding of male heroin addicts under methadone treatment: psychometric and neuroendocrine correlates.
    Gerra G; Zaimovic A; Raggi MA; Giusti F; Delsignore R; Bertacca S; Brambilla F
    Drug Alcohol Depend; 2001 Dec; 65(1):85-95. PubMed ID: 11714593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kappa opioid receptor antagonism and chronic antidepressant treatment have beneficial activities on social interactions and grooming deficits during heroin abstinence.
    Lalanne L; Ayranci G; Filliol D; Gavériaux-Ruff C; Befort K; Kieffer BL; Lutz PE
    Addict Biol; 2017 Jul; 22(4):1010-1021. PubMed ID: 27001273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients.
    Zaaijer ER; van Dijk L; de Bruin K; Goudriaan AE; Lammers LA; Koeter MW; van den Brink W; Booij J
    Psychopharmacology (Berl); 2015 Jul; 232(14):2597-607. PubMed ID: 25757673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addicts.
    Landabaso MA; Iraurgi I; Jiménez-Lerma JM; Sanz J; Fernádez de Corres B; Araluce K; Calle R; Gutiérrez-Fraile M
    Addiction; 1998 May; 93(5):739-44. PubMed ID: 9692272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of olanzapine on aggressiveness in heroin dependent patients.
    Gerra G; Di Petta G; D'Amore A; Iannotta P; Bardicchia F; Falorni F; Coacci A; Strepparola G; Campione G; Lucchini A; Vedda G; Serio G; Manzato E; Antonioni M; Bertacca S; Moi G; Zaimovic A
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1291-8. PubMed ID: 16766110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine and behavioural responses to opioid receptor-antagonist during heroin detoxification: relationship with personality traits.
    Gerra G; Ceresini S; Esposito A; Zaimovic A; Moi G; Bussandri M; Raggi MA; Molina E
    Int Clin Psychopharmacol; 2003 Sep; 18(5):261-9. PubMed ID: 12920386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo.
    Tauscher-Wisniewski S; Nilsson M; Caldwell C; Plewes J; Allen AJ
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):713-8. PubMed ID: 17979590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacotherapy in heroin addiction: pharmacological approaches to remission stabilization and recurrence prevention].
    Grinenko AIa; Krupitskiĭ EM; Zvartau EE
    Vestn Ross Akad Med Nauk; 2003; (10):54-6. PubMed ID: 14598513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychological functioning in buprenorphine maintained patients versus abstinent heroin abusers on naltrexone hydrochloride therapy.
    Messinis L; Lyros E; Andrian V; Katsakiori P; Panagis G; Georgiou V; Papathanasopoulos P
    Hum Psychopharmacol; 2009 Oct; 24(7):524-31. PubMed ID: 19650155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming opioid blockade from depot naltrexone (Prodetoxon).
    Kruptisky EM; Burakov AM; Tsoy MV; Egorova VY; Slavina TY; Grinenko AY; Zvartau EE; Woody GE
    Addiction; 2007 Jul; 102(7):1164-5. PubMed ID: 17498182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased oxytocin levels among abstinent heroin addicts: Association with aggressiveness, psychiatric symptoms and perceived childhood neglect.
    Gerra LM; Gerra G; Mercolini L; Manfredini M; Somaini L; Pieri CM; Antonioni M; Protti M; Ossola P; Marchesi C
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Apr; 75():70-76. PubMed ID: 28093220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of prolactin response to d-fenfluramine to behavioral and questionnaire assessments of aggression in personality-disordered men.
    Coccaro EF; Berman ME; Kavoussi RJ; Hauger RL
    Biol Psychiatry; 1996 Aug; 40(3):157-64. PubMed ID: 8830948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
    Hulse GK; Morris N; Arnold-Reed D; Tait RJ
    Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prediction of drug dependence from expectancy for hostility while intoxicated.
    Walter D; Nagoshi C; Muntaner C; Haertzen CA
    Int J Addict; 1990 Oct; 25(10):1151-68. PubMed ID: 2090620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence.
    Wang AL; Elman I; Lowen SB; Blady SJ; Lynch KG; Hyatt JM; O'Brien CP; Langleben DD
    Transl Psychiatry; 2015 Mar; 5(3):e531. PubMed ID: 25781230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.